Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
DCF Valuation
Base-case fair value
€74.35
Intrinsic €99.14 · 25% MOS
Current price: €90.25
Base-case summary
Our base-case DCF for BioNTech SE (BNTX) projects 10 years of free cash flow growth at 2.0% for years 1–5 and 1.0% for years 6–10, anchored to a default 8% growth assumption, then applies a 2.5% perpetual growth rate and a 8.0% discount rate. Starting from €606M in trailing free cash flow, this produces an intrinsic value of €99.14 per share. A 25% safety margin gives a fair value of €74.35, suggesting the stock is currently 18% overvalued against the €90.25 market price.
See 3 scenarios side by side
Conservative, Base, and Optimistic fair values, plus the sensitivity matrix and FCF history. Free account.
Model inputs
TTM Free Cash Flow
€606M
Cash & equivalents
€14.9B
Total debt
€267M
Shares outstanding
253M